Payment overview · 2025
General Payments
$236.60
14 reported records · 10 companies
Healthcare provider profile · identity verified
Brandon D Sohm, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEVADA, MO · NPI 1114242997
Verified facts
What the public records show
CMS Open Payments records show Brandon D Sohm, MD received $236.60 in general payments during 2025 across 14 reported records.
Phathom Pharmaceuticals, Inc. accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.31 | 18.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.77 | 13.4% | 2 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $31.27 | 13.2% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $26.44 | 11.2% | 1 | 2025 |
| Hydrofera LLC | Unresolved — no canonical attribution shown | $24.42 | 10.3% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $21.59 | 9.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $15.34 | 6.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.23 | 6.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.12 | 6.0% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $14.11 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $236.60 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $43.31 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.77 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $31.27 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $31.27 | 2 | 2025 |
Source payment records
|
|||||
| CEREZYME Normalized: cerezyme |
Biological | GENZYME CORPORATION | $26.44 | 1 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $26.44 | 1 | 2025 |
Source payment records
|
|||||
| HYDROFERA BLUE Normalized: hydrofera blue |
Device | Hydrofera LLC | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 198 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 148 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 34 |
| Gabapentin | Gabapentin | 140 | 44 |
| Furosemide | Furosemide | 134 | 40 |
| Losartan Potassium | Losartan Potassium | 113 | 44 |
| Potassium Chloride | Potassium Chloride | 89 | 23 |
| Lisinopril | Lisinopril | 86 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 21 |
| Omeprazole | Omeprazole | 82 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 23 |
| Trazodone Hcl | Trazodone Hcl | 79 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 20 |
| Pregabalin | Pregabalin | 76 | 16 |
| Naproxen | Naproxen | 74 | 17 |
| Amlodipine Besylate | Amlodipine Besylate | 72 | 28 |
| Eliquis | Apixaban | 68 | 17 |
| Meloxicam | Meloxicam | 65 | 25 |
| Alendronate Sodium | Alendronate Sodium | 62 | 19 |
| Buspirone Hcl | Buspirone Hcl | 60 | suppressed |
| Spironolactone | Spironolactone | 60 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 25 |
| Sertraline Hcl | Sertraline Hcl | 56 | 16 |
| Tramadol Hcl | Tramadol Hcl | 53 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | 14 |
| Carvedilol | Carvedilol | 49 | 19 |
| Metformin Hcl | Metformin Hcl | 48 | 18 |
| Cefdinir | Cefdinir | 45 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 18 |
| Famotidine | Famotidine | 43 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 13 |
| Prednisone | Prednisone | 37 | 28 |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 15 |
| Simvastatin | Simvastatin | 35 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | 12 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 11 |
| Metolazone | Metolazone | 27 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $236.60 · 14 records | Phathom Pharmaceuticals, Inc. | AIRSUPRA, CAPVAXIVE, CEREZYME, FABRAZYME, GARDASIL 9, HYDROFERA BLUE, JOURNAVX, Kerecis GraftGuide, Kerecis SurgiClose, Omnipod, TONMYA, VAXELIS, VAXNEUVANCE, VOQUEZNA, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error